≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Hereditary factor VIII deficiency

DOID EFO Endpoint Browser PheWeb

D3_HEREDFVIIIDEF

obsolete_factor VIII deficiency: An X-linked disease that has_material_basis_in Factor VIII deficiency, which results in the formation of fibrin deficient clots which makes coagulation much more prolonged. The disease is inherited as an X-linked recessive trait.

Suggest a new description

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — D66
  • Hospital discharge: ICD-9 — 2860
  • Hospital discharge: ICD-8 — 2860
  • Cause of death: ICD-10 — D66
  • Cause of death: ICD-9 — 2860
  • Cause of death: ICD-8 — 2860

2 out of 7 registries used, show all original rules.

101

4. Check minimum number of events

None

101

5. Include endpoints

None

101

6. Filter based on genotype QC (FinnGen only)

96

Control definitions (FinnGen only)

Control exclude
D3_COAGDEF_PURPUR_HAEMORRHAGIC

Extra metadata

Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF2
Parent code in ICD-10
D65-D69
Name in latin
Deficientia hereditaria factoris VIII

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 723 205 511
Only index persons 586 187 399
Unadjusted period prevalence (%)
Whole population 0.01 0.01 0.01
Only index persons 0.01 0.01 0.02
Median age at first event (years)
Whole population 19.22 36.79 11.69
Only index persons 19.32 35.25 11.86

-FinnGen-

Key figures

All Female Male
Number of individuals 96 41 55
Unadjusted period prevalence (%) 0.02 0.01 0.03
Median age at first event (years) 24.71 34.63 17.32

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
101
Matched controls
1010
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D66
ICD-10 Finland
Hereditary factor VIII deficiency
+∞
120.1
90
*
B02AA02
ATC
tranexamic acid; systemic
21.6
57.2
64
75
126
Kela drug reimbursment
Chronic coagulation defects
+∞
52.8
46
*
B02BD02
ATC
coagulation factor VIII; parenteral
+∞
39.1
35
*
2860A
ICD-9 Finland
Coagulation defects, Congenital factor VIII disorder
+∞
27.3
25
*
B02BX06
ATC
emicizumab; parenteral
+∞
25.0
23
*
M362, D66,
ICD-10 Finland
+∞
25.0
23
*
28600
ICD-8 Finland
Coagulation defects, Haemophilia
+∞
23.9
22
*
NH1AA
NOMESCO Finland
Ankle X-ray examination without contrast
11.2
23.5
29
35
3047, ,
Kela drug reimbursment
+∞
22.8
21
*
1520, ,
Kela drug reimbursment
+∞
22.8
21
*
ZX120
NOMESCO Finland
Intravenous
9.5
21.7
31
45
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
14.3
15.7
27
25
D68.0
ICD-10 Finland
Von Willebrand disease
+∞
15.0
14
*
M36.2
ICD-10 Finland
Haemophilic arthropathy
+∞
15.0
14
*
M01AE01
ATC
ibuprofen; systemic, rectal
0.2
14.5
48
826
B18.2
ICD-10 Finland
Chronic viral hepatitis C
33.6
13.5
17
6
D68.8
ICD-10 Finland
Other specified coagulation defects
+∞
11.7
11
*
Z31.5
ICD-10 Finland
Genetic counselling
6.3
10.6
20
38
M19.2
ICD-10 Finland
Other secondary arthrosis
61.0
9.9
11
*
TPH90
NOMESCO Finland
Removal of fixed intravenous catheter
24.5
9.6
13
6
R4110
NOMESCO Finland
Physiotherapy
3.6
8.8
44
179
D68.9
ICD-10 Finland
Coagulation defect, unspecified
+∞
8.4
8
*
T81.0
ICD-10 Finland
Haemorrhage and haematoma complicating a procedure, not elsewhere classified
7.5
8.2
19
30
R04.0
ICD-10 Finland
Epistaxis
7.3
8.0
19
31
Y83
ICD-10 Finland
Surgical operation and other surgical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
7.6
7.9
18
28
NK1XE
NOMESCO Finland
Other ultrasound examinnation of muscle or tendon
27.4
7.7
10
*
NG1AA
NOMESCO Finland
Knee X-ray examination without contrast
4.6
7.7
21
55
NC1AA
NOMESCO Finland
Elbow X-ray examination without contrast
9.1
7.4
15
19
D67
ICD-10 Finland
Hereditary factor IX deficiency
+∞
7.4
7
*
2BD02, ,
NOMESCO Finland
+∞
7.4
7
*
M25.0
ICD-10 Finland
Haemarthrosis
22.0
7.3
10
5
TPX10
NOMESCO Finland
Implantation of vascular injection port
11.3
7.3
13
13
T81.4
ICD-10 Finland
Infection following a procedure, not elsewhere classified
4.8
7.2
18
44
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
4.0
7.1
23
69
S82.3
ICD-10 Finland
Fracture of lower end of tibia
24.4
6.8
9
*
ZXA05
NOMESCO Finland
Left side
3.3
6.5
32
126
O99.1
ICD-10 Finland
Other diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism complicating pregnancy, childbirth and the puerperium
74.3
6.5
7
*
NHG20
NOMESCO Finland
Fusion of talocrural joint
+∞
6.3
6
*
2BD06, ,
NOMESCO Finland
+∞
6.3
6
*

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Inpatient Hospital
21 [8717]
4.3e-01
7.1e-01
2.6e+00
1.0e+50
2.4e+00
2.0e+00
1.3e+00
cases:42.86%
controls:32.75%
cases:23.44%
controls:13.13%
cases:9.38%
controls:0.79%
cases:21.88%
controls:0.00%
cases:17.19%
controls:1.90%
cases:39.06%
controls:7.81%
cases:59.32%
controls:28.25%
27
205
36
421
15
83
49
549
6
5
58
627
14
0
50
632
11
12
53
620
25
49
39
578
35
165
24
419
Emergency Room Visit
ER [9203]
6.9e-01
9.7e-01
2.7e+00
1.0e+50
2.5e+00
1.6e+00
1.1e+00
cases:44.44%
controls:28.59%
cases:26.56%
controls:12.03%
cases:10.94%
controls:0.79%
cases:15.63%
controls:0.00%
cases:10.94%
controls:0.95%
cases:34.38%
controls:9.89%
cases:59.32%
controls:32.71%
28
179
35
447
17
76
47
556
7
5
57
627
10
0
54
632
7
6
57
626
22
62
42
565
35
191
24
393
tranexamic acid; oral, parenteral
B02AA02 [21601036]
2.6e+00
—
—
—
—
2.4e+00
2.9e+00
cases:17.46%
controls:1.60%
—
—
—
—
—
—
—
—
cases:12.50%
controls:1.28%
cases:30.51%
controls:2.23%
11
10
52
616
—
—
—
—
8
8
56
619
18
13
41
571
Outpatient Visit
OP [9202]
3.6e-01
1.1e+00
1.5e+00
—
1.9e+00
1.2e+00
1.3e+00
cases:66.67%
controls:58.31%
cases:65.63%
controls:38.45%
cases:31.25%
controls:9.18%
—
—
cases:42.19%
controls:9.97%
cases:70.31%
controls:40.51%
cases:88.14%
controls:67.64%
42
365
21
261
42
243
22
389
20
58
44
574
—
27
63
37
569
45
254
19
373
52
395
7
189
Medical doctor
Z2221 [2001311556]
1.2e+00
1.8e+00
—
—
—
2.4e+00
1.8e+00
cases:7.94%
controls:2.56%
cases:10.94%
controls:1.90%
—
—
—
—
—
—
cases:10.94%
controls:1.12%
cases:22.03%
controls:4.28%
5
16
58
610
7
12
57
620
—
—
—
7
7
57
620
13
25
46
559
Internal Medicine
11 [38004456]
5.6e-01
1.1e+00
1.3e+00
1.0e+50
2.2e+00
1.2e+00
1.0e+00
cases:30.16%
controls:19.81%
cases:21.88%
controls:8.54%
cases:9.38%
controls:2.69%
cases:21.88%
controls:0.00%
cases:14.06%
controls:1.74%
cases:20.31%
controls:7.34%
cases:37.29%
controls:17.29%
19
124
44
502
14
54
50
578
6
17
58
615
14
0
50
632
9
11
55
621
13
46
51
581
22
101
37
483
Obstetrics / Gynecology
16 [38004461]
3.4e-02
1.4e+00
—
1.0e+50
2.4e+00
1.1e+00
9.0e-01
cases:19.05%
controls:18.53%
cases:23.44%
controls:7.12%
—
—
cases:23.44%
controls:0.00%
cases:12.50%
controls:1.27%
cases:20.31%
controls:7.50%
cases:33.90%
controls:17.29%
12
116
51
510
15
45
49
587
—
15
0
49
632
8
8
56
624
13
47
51
580
20
101
39
483
Hematology
82 [38004501]
—
—
—
1.0e+50
—
—
3.7e+00
—
—
—
—
—
—
cases:18.75%
controls:0.00%
—
—
—
—
cases:32.20%
controls:1.20%
—
—
—
12
0
52
632
—
—
19
7
40
577
Case Management Agency
251B00000X [38004193]
1.1e-01
3.7e-03
6.3e-01
2.7e+00
6.8e-01
4.3e-01
3.9e-01
cases:38.10%
controls:35.62%
cases:31.25%
controls:31.17%
cases:18.75%
controls:10.92%
cases:10.94%
controls:0.79%
cases:20.31%
controls:11.39%
cases:43.75%
controls:33.49%
cases:67.80%
controls:58.73%
24
223
39
403
20
197
44
435
12
69
52
563
7
5
57
627
13
72
51
560
28
210
36
417
40
343
19
241
Outpatient Hospital
22 [8756]
7.1e-01
1.4e-01
—
1.0e+50
—
1.3e+00
1.3e+00
cases:38.10%
controls:23.16%
cases:9.38%
controls:8.23%
—
—
cases:9.38%
controls:0.00%
—
—
cases:18.75%
controls:5.90%
cases:49.15%
controls:20.89%
24
145
39
481
6
52
58
580
—
6
0
58
632
—
12
37
52
590
29
122
30
462
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
-7.0e-02
7.5e-01
—
—
2.6e+00
1.1e+00
2.4e-01
cases:11.11%
controls:11.82%
cases:12.50%
controls:6.33%
—
—
—
—
cases:9.38%
controls:0.79%
cases:17.19%
controls:6.38%
cases:23.73%
controls:19.69%
7
74
56
552
8
40
56
592
—
—
6
5
58
627
11
40
53
587
14
115
45
469
CBC panel - Blood by Automated count
58410-2 [40761511]
2.4e-01
—
2.0e+00
—
2.4e+00
7.2e-01
5.8e-02
cases:15.87%
controls:12.94%
—
—
cases:7.81%
controls:1.11%
—
—
cases:10.94%
controls:1.11%
cases:14.06%
controls:7.34%
cases:22.03%
controls:21.06%
10
81
53
545
—
5
7
59
625
—
7
7
57
625
9
46
55
581
13
123
46
461
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
2.8e-01
1.4e-01
—
1.0e+50
2.4e+00
9.0e-01
-3.4e-02
cases:14.29%
controls:11.18%
cases:9.38%
controls:8.23%
—
—
cases:7.81%
controls:0.00%
cases:9.38%
controls:0.95%
cases:17.19%
controls:7.81%
cases:20.34%
controls:20.89%
9
70
54
556
6
52
58
580
—
5
0
59
632
6
6
58
626
11
49
53
578
12
122
47
462
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
3.0e-01
1.4e-01
—
1.0e+50
2.4e+00
9.0e-01
-2.3e-02
cases:14.29%
controls:11.02%
cases:9.38%
controls:8.23%
—
—
cases:7.81%
controls:0.00%
cases:9.38%
controls:0.95%
cases:17.19%
controls:7.81%
cases:20.34%
controls:20.72%
9
69
54
557
6
52
58
580
—
5
0
59
632
6
6
58
626
11
49
53
578
12
121
47
463
Intravenous
ZX120 [2001311495]
2.4e+00
—
—
—
—
—
—
cases:7.94%
controls:0.80%
—
—
—
—
—
—
—
—
—
—
—
—
5
5
58
621
—
—
—
—
—
—
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
1.7e-01
6.9e-02
—
—
2.3e+00
7.7e-01
-1.4e-01
cases:14.29%
controls:12.30%
cases:10.94%
controls:10.28%
—
—
—
—
cases:10.94%
controls:1.27%
cases:17.19%
controls:8.77%
cases:20.34%
controls:22.77%
9
77
54
549
7
65
57
567
—
—
7
8
57
624
11
55
53
572
12
133
47
451
Platelets [#/volume] in Blood
26515-7 [3007461]
5.3e-02
0.0e+00
1.8e+00
—
2.2e+00
6.1e-01
-1.0e-01
cases:15.87%
controls:15.18%
cases:12.50%
controls:12.50%
cases:10.94%
controls:2.06%
—
—
cases:14.06%
controls:1.74%
cases:18.75%
controls:11.16%
cases:25.42%
controls:27.40%
10
95
53
531
8
79
56
553
7
13
57
619
—
9
11
55
621
12
70
52
557
15
160
44
424
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
5.3e-02
0.0e+00
1.8e+00
—
2.2e+00
6.1e-01
-1.3e-01
cases:15.87%
controls:15.18%
cases:12.50%
controls:12.50%
cases:10.94%
controls:2.06%
—
—
cases:14.06%
controls:1.74%
cases:18.75%
controls:11.16%
cases:25.42%
controls:27.91%
10
95
53
531
8
79
56
553
7
13
57
619
—
9
11
55
621
12
70
52
557
15
163
44
421
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
5.3e-02
1.5e-02
1.8e+00
—
2.2e+00
6.1e-01
-1.3e-01
cases:15.87%
controls:15.18%
cases:12.50%
controls:12.34%
cases:10.94%
controls:2.06%
—
—
cases:14.06%
controls:1.74%
cases:18.75%
controls:11.16%
cases:25.42%
controls:27.91%
10
95
53
531
8
78
56
554
7
13
57
619
—
9
11
55
621
12
70
52
557
15
163
44
421
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
1.3e-01
1.2e-01
—
—
2.2e+00
7.8e-01
-9.1e-02
cases:14.29%
controls:12.78%
cases:10.94%
controls:9.81%
—
—
—
—
cases:9.38%
controls:1.11%
cases:15.63%
controls:7.81%
cases:22.03%
controls:23.63%
9
80
54
546
7
62
57
570
—
—
6
7
58
625
10
49
54
578
13
138
46
446
paracetamol; oral, parenteral, rectal
N02BE01 [21604344]
2.4e-01
5.6e-01
-1.0e+50
—
2.2e+00
7.1e-01
3.4e-01
cases:23.81%
controls:19.81%
cases:14.06%
controls:8.54%
cases:0.00%
controls:1.27%
—
—
cases:9.38%
controls:1.11%
cases:17.19%
controls:9.25%
cases:35.59%
controls:28.25%
15
124
48
502
9
54
55
578
0
8
64
624
—
6
7
58
625
11
58
53
569
21
165
38
419
aPTT in Platelet poor plasma by Coagulation assay
14979-9 [3018677]
—
—
—
—
—
2.3e+00
2.2e+00
—
—
—
—
—
—
—
—
—
—
cases:7.81%
controls:0.80%
cases:13.56%
controls:1.71%
—
—
—
—
—
5
5
59
622
8
10
51
574
Leukocytes [#/volume] in Blood
26464-8 [3010813]
5.3e-02
0.0e+00
1.8e+00
—
2.1e+00
6.1e-01
-1.2e-01
cases:15.87%
controls:15.18%
cases:12.50%
controls:12.50%
cases:10.94%
controls:2.06%
—
—
cases:12.50%
controls:1.74%
cases:18.75%
controls:11.16%
cases:25.42%
controls:27.74%
10
95
53
531
8
79
56
553
7
13
57
619
—
8
11
56
621
12
70
52
557
15
162
44
422
MCH [Entitic mass]
28539-5 [3035941]
5.3e-02
0.0e+00
1.8e+00
—
2.1e+00
6.1e-01
-1.3e-01
cases:15.87%
controls:15.18%
cases:12.50%
controls:12.50%
cases:10.94%
controls:2.06%
—
—
cases:12.50%
controls:1.74%
cases:18.75%
controls:11.16%
cases:25.42%
controls:27.91%
10
95
53
531
8
79
56
553
7
13
57
619
—
8
11
56
621
12
70
52
557
15
163
44
421
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
5.3e-02
0.0e+00
1.8e+00
—
2.1e+00
6.1e-01
-1.3e-01
cases:15.87%
controls:15.18%
cases:12.50%
controls:12.50%
cases:10.94%
controls:2.06%
—
—
cases:12.50%
controls:1.74%
cases:18.75%
controls:11.16%
cases:25.42%
controls:27.91%
10
95
53
531
8
79
56
553
7
13
57
619
—
8
11
56
621
12
70
52
557
15
163
44
421
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
5.3e-02
-1.4e-02
1.8e+00
—
2.1e+00
6.1e-01
-1.3e-01
cases:15.87%
controls:15.18%
cases:12.50%
controls:12.66%
cases:10.94%
controls:2.06%
—
—
cases:12.50%
controls:1.74%
cases:18.75%
controls:11.16%
cases:25.42%
controls:27.91%
10
95
53
531
8
80
56
552
7
13
57
619
—
8
11
56
621
12
70
52
557
15
163
44
421
Spontaneous vertex delivery
O80.0 [45577661]
—
-1.0e+50
—
—
—
1.9e+00
—
—
—
cases:0.00%
controls:1.58%
—
—
—
—
—
—
cases:10.94%
controls:1.75%
—
—
—
0
10
64
622
—
—
—
7
11
57
616
—
Outcome of delivery
Z37 [45581024]
-2.8e-02
—
—
—
—
1.7e+00
—
cases:7.94%
controls:8.15%
—
—
—
—
—
—
—
—
cases:12.50%
controls:2.55%
—
—
5
51
58
575
—
—
—
—
8
16
56
611
—
Laboratory Visit
OMOP4822461 [32036]
-7.7e-02
-2.7e-02
1.3e+00
—
1.7e+00
1.6e-01
-2.6e-01
cases:15.87%
controls:16.93%
cases:15.63%
controls:15.98%
cases:12.50%
controls:3.80%
—
—
cases:15.63%
controls:3.32%
cases:18.75%
controls:16.43%
cases:27.12%
controls:32.53%
10
106
53
520
10
101
54
531
8
24
56
608
—
10
21
54
611
12
103
52
524
16
190
43
394
Scheduled procedure
ZXD10 [2001311387]
8.9e-01
—
—
—
—
—
1.6e+00
cases:9.52%
controls:4.15%
—
—
—
—
—
—
—
—
—
—
cases:15.25%
controls:3.60%
6
26
57
600
—
—
—
—
—
9
21
50
563
furosemide; oral, parenteral
C03CA01 [21601518]
—
—
—
—
—
1.1e+00
1.6e+00
—
—
—
—
—
—
—
—
—
—
cases:7.81%
controls:2.87%
cases:16.95%
controls:4.11%
—
—
—
—
—
5
18
59
609
10
24
49
560
Panorama tomography of teeth and jaws or similar X-ray examination
EB1HA [2001301913]
—
—
—
—
—
—
1.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:18.64%
controls:4.97%
—
—
—
—
—
—
11
29
48
555
Orthopedic Surgery
20 [38004465]
8.2e-01
1.3e+00
—
—
—
—
1.3e+00
cases:15.87%
controls:7.67%
cases:9.38%
controls:2.85%
—
—
—
—
—
—
—
—
cases:30.51%
controls:10.79%
10
48
53
578
6
18
58
614
—
—
—
—
18
63
41
521
diazepam; oral, parenteral, rectal
N05BA01 [21604566]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:1.11%
—
—
—
—
—
—
cases:0.00%
controls:0.80%
cases:0.00%
controls:1.88%
—
0
7
64
625
—
—
—
0
5
64
622
0
11
59
573
Cough
R05 [2002000886]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.76%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.91%
0
11
63
615
—
—
—
—
—
0
17
59
567
fluticasone furoate
R03BA09 [45893496]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:3.51%
cases:0.00%
controls:2.22%
—
—
—
—
—
—
cases:0.00%
controls:1.44%
—
—
0
22
63
604
0
14
64
618
—
—
—
0
9
64
618
—
tizanidine; oral
M03BX02 [21604116]
4.0e-01
—
—
—
—
—
3.2e-02
cases:17.46%
controls:12.46%
—
—
—
—
—
—
—
—
—
—
cases:13.56%
controls:13.18%
11
78
52
548
—
—
—
—
—
8
77
51
507
Treatment of a patient needing special arrangements
WYA30 [2001310874]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.03%
0
6
63
620
—
—
—
—
—
0
6
59
578
Curettage of uterus after delivery or abortion
MBA03 [2001306930]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.12%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
63
619
—
—
—
—
—
—
Glucose [Presence] in Urine by Test strip
25428-4 [3009261]
—
—
—
—
—
—
-2.1e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.47%
controls:10.27%
—
—
—
—
—
—
5
60
54
524
Polyp of corpus uteri
N84.0 [45596887]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.86%
—
—
—
—
—
—
0
5
59
579
Periodontal treatment
SDA03 [2001310328]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:3.35%
cases:0.00%
controls:1.27%
—
—
—
—
—
—
—
—
—
—
0
21
63
605
0
8
64
624
—
—
—
—
—
Proliferative diabetic retinopathy and Type 1 diabetes mellitus, With ophthalmic complications
H36.03*E10.3 [2000503982]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.86%
—
—
—
—
—
—
0
5
59
579
drospirenone and ethinylestradiol
G03AA12 [21602485]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.12%
—
—
—
—
—
—
—
0
7
64
620
—
Unilateral or unspecified inguinal hernia, without obstruction or gangrene
K40.9 [45543307]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.12%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
63
619
—
—
—
—
—
—
nystatin; oral
A07AA02 [21600604]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
63
621
—
—
—
—
—
—
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
1.6e-01
—
—
—
—
1.0e+00
1.8e-01
cases:7.94%
controls:6.87%
—
—
—
—
—
—
—
—
cases:10.94%
controls:4.31%
cases:11.86%
controls:10.10%
5
43
58
583
—
—
—
—
7
27
57
600
7
59
52
525
amitriptyline and psycholeptics
N06CA01 [21604789]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.12%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
0
7
63
619
—
—
—
—
0
5
64
622
—
lovastatin; oral
C10AA02 [21601857]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
63
621
—
—
—
—
—
—
Diarrhoea
D11 [2002000310]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.03%
—
—
—
—
—
—
0
6
59
578
Exposure to unspecified factor
X59 [45756412]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.95%
—
—
—
—
—
—
—
—
—
—
—
0
6
64
626
—
—
—
—
—
Ear pain/earache
H01 [2002000475]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.86%
—
—
—
—
—
—
0
5
59
579
Menopausal and female climacteric states
N95.1 [45548683]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.54%
—
—
—
—
—
—
0
9
59
575
cetirizine; oral
R06AE07 [21603497]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:8.63%
—
—
—
—
—
—
—
—
—
—
—
—
0
54
63
572
—
—
—
—
—
—
pivmecillinam; oral
J01CA08 [21602827]
4.8e-01
—
—
—
—
—
5.7e-01
cases:11.11%
controls:7.19%
—
—
—
—
—
—
—
—
—
—
cases:15.25%
controls:9.25%
7
45
56
581
—
—
—
—
—
9
54
50
530
Teaching
WZC30 [2001310891]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.44%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
63
617
—
—
—
—
—
—
Other primary gonarthrosis
M17.1 [45596493]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
63
620
—
—
—
—
—
—
Thorax X-ray examination outside radiological department
GD1UA [2001303652]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.37%
—
—
—
—
—
—
0
8
59
576
diclofenac; ointment
M02AA15 [21604051]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.88%
—
—
—
—
—
—
0
11
59
573
dexamethasone and antiinfectives
S03CA01 [21605206]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.03%
—
—
—
—
—
—
0
6
59
578
Acute vaginitis
N76.0 [45543891]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
63
620
—
—
—
—
—
—
Chlamydia trachomatis DNA [Presence] in Specimen by NAA with probe detection
21613-5 [3006093]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.44%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
63
617
—
—
—
—
—
—
Supervision of normal first pregnancy
Z34.0 [45595500]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.28%
cases:0.00%
controls:1.54%
0
6
63
620
—
—
—
—
0
8
64
619
0
9
59
575
Restoration involving the entire crown of the tooth
SFA40 [2001310361]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.57%
—
—
—
—
—
—
0
15
59
569
Deposits [accretions] on teeth betel
K03.65 [2000502690]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
0
6
63
620
—
—
—
—
0
6
64
621
—
Public health laboratory ask at order entry panel
81959-9 [21494755]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.92%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.20%
0
12
63
614
—
—
—
—
—
0
7
59
577
General examination of pregnant woman
XMA22 [2001306916]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.88%
—
0
5
64
627
—
—
—
—
0
11
59
573
Dental impressions
SBB10 [2001310299]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.28%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
63
618
—
—
—
—
—
—
Hand Surgery
40 [38004480]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
0
6
64
621
—
Antenatal screening
243787009 [4087235]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
63
621
—
—
—
—
—
—
Dental examination
Z01.2 [45581002]
—
—
—
—
—
—
3.5e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:10.17%
controls:7.36%
—
—
—
—
—
—
6
43
53
541
Operation for humeroscapular osteochondritis, arthroscopic
NBF25 [2001307294]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.86%
—
—
—
—
—
—
0
5
59
579
12 lead EKG panel
34534-8 [3044889]
1.6e-01
—
—
—
—
—
2.4e-01
cases:7.94%
controls:6.87%
—
—
—
—
—
—
—
—
—
—
cases:11.86%
controls:9.59%
5
43
58
583
—
—
—
—
—
7
56
52
528
Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection
40987-0 [3043924]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.20%
—
—
—
—
—
—
0
7
59
577
Anomalies of dental arch relationship
K07.25 [2000502771]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
63
620
—
—
—
—
—
—
enalapril and diuretics
C09BA02 [21601804]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.20%
—
—
—
—
—
—
0
7
59
577
Fasting glucose [Moles/volume] in Serum or Plasma
14771-0 [3018251]
3.3e-01
—
—
—
—
—
3.7e-02
cases:12.70%
controls:9.42%
—
—
—
—
—
—
—
—
—
—
cases:16.95%
controls:16.44%
8
59
55
567
—
—
—
—
—
10
96
49
488
Extraction of tooth
EBA00 [2001301923]
—
—
—
—
—
-1.0e+50
9.8e-01
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.75%
cases:11.86%
controls:4.79%
—
—
—
—
—
0
11
64
616
7
28
52
556
Contraception intrauterine
W12 [2002001212]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.57%
—
—
—
—
—
—
0
15
59
569
scopolamine
A04AD01 [21600499]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.37%
—
—
—
—
—
—
0
8
59
576
Counselling/guidance promoting independent living
SPAT1222 [2001700323]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.03%
—
—
—
—
—
—
0
6
59
578
tiotropium bromide; inhalant
R03BB04 [21603296]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
—
0
5
64
622
—
Specific gravity of Urine by Test strip
5811-5 [3000330]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.54%
—
—
—
—
—
—
0
9
59
575
EKG study
11524-6 [3013512]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.95%
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
0
6
64
626
—
—
—
0
5
64
622
—
Abnormal findings in specimens from female genital organs, abnormal cytological findings
R87.6 [45558487]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.44%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
63
617
—
—
—
—
—
—
Emergency visit or other similar visit involving procedures
WYA05 [2001310871]
—
-1.0e+50
—
—
—
—
-2.0e-01
—
—
cases:0.00%
controls:2.22%
—
—
—
—
—
—
—
—
cases:10.17%
controls:12.16%
—
0
14
64
618
—
—
—
—
6
71
53
513
Snapping jaw
K07.60 [2000502791]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.03%
—
—
—
—
—
—
0
6
59
578
Treatment-related counselling outside office
SPAT1249 [2001700350]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.12%
—
—
—
—
—
—
—
0
7
64
620
—
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
—
—
—
—
—
—
2.3e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.47%
controls:6.85%
—
—
—
—
—
—
5
40
54
544
Acute appendicitis, unspecified
K35.9 [45557651]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
63
621
—
—
—
—
—
—
Counselling and guidance related to nutrition and weight management
SPAT1306 [2001700407]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.20%
—
—
—
—
—
—
0
7
59
577
Methemoglobin/Hemoglobin.total in Venous blood
2617-9 [3024889]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.86%
—
—
—
—
—
—
0
5
59
579
Physiotherapy
R4110 [2001310233]
—
—
—
—
—
—
9.6e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.47%
controls:3.42%
—
—
—
—
—
—
5
20
54
564
Body height measure
50373000 [4177340]
-1.3e+00
-1.0e+50
—
—
—
—
—
cases:7.94%
controls:23.16%
cases:0.00%
controls:6.33%
—
—
—
—
—
—
—
—
—
—
5
145
58
481
0
40
64
592
—
—
—
—
—
Transvaginal ultrasound examination of uterus, parametria and lower abdomen
LC2BE [2001306544]
—
—
—
—
—
—
9.4e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:11.86%
controls:4.97%
—
—
—
—
—
—
7
29
52
555
Intubation
WX704 [2001310820]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.80%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.03%
0
5
63
621
—
—
—
—
—
0
6
59
578
Complex partial epileptic seizure with secondary generalization
G40.22 [2000502141]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.86%
—
—
—
—
—
—
0
5
59
579
potassium chloride; oral
A12BA01 [21600877]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.96%
cases:0.00%
controls:0.79%
—
—
—
—
—
—
—
—
—
—
0
6
63
620
0
5
64
627
—
—
—
—
—
alfuzosin; oral
G04CA01 [21602668]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.86%
—
—
—
—
—
—
0
5
59
579
Acute spinal anesthesia for delivery
WX321 [2001310800]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.20%
—
—
—
—
—
—
0
7
59
577
Cardiology
6 [38004451]
8.6e-01
—
—
—
—
—
1.1e+00
cases:7.94%
controls:3.51%
—
—
—
—
—
—
—
—
—
—
cases:11.86%
controls:4.11%
5
22
58
604
—
—
—
—
—
7
24
52
560
insulin degludec; parenteral
A10AE06 [43534747]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.20%
—
—
—
—
—
—
0
7
59
577
Hemoglobin [Mass/volume] in Arterial blood
30313-1 [3002173]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.03%
—
—
—
—
—
—
0
6
59
578
dexrabeprazole
A02BC07 [45893509]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.86%
—
—
—
—
—
—
0
5
59
579
Oral and dental health check by dental hygienist or dental assistant
SAB02 [2001310280]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.80%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.88%
0
5
63
621
—
—
—
—
—
0
11
59
573
carbamazepine; oral, rectal
N03AF01 [21604417]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.80%
cases:0.00%
controls:0.79%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.20%
0
5
63
621
0
5
64
627
—
—
—
—
0
7
59
577
Detailed morfological ultrasound examination of fetus
MA2HE [2001306836]
—
1.9e+00
—
—
—
—
—
—
—
cases:7.81%
controls:1.27%
—
—
—
—
—
—
—
—
—
—
—
5
8
59
624
—
—
—
—
—
insulin (beef); parenteral
A10AD02 [21600730]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.95%
—
—
—
—
—
—
—
—
0
6
64
626
—
—
fluconazole; oral, parenteral
J02AC01 [21603080]
8.9e-02
—
-1.0e+50
—
—
1.4e+00
2.6e-01
cases:9.52%
controls:8.79%
—
—
cases:0.00%
controls:0.79%
—
—
—
—
cases:9.38%
controls:2.39%
cases:8.47%
controls:6.68%
6
55
57
571
—
0
5
64
627
—
—
6
15
58
612
5
39
54
545
Streptococcus.beta-hemolytic [Presence] in Throat by Organism specific culture
546-2 [3024135]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:3.94%
—
—
—
—
—
—
0
23
59
561
Thyrotropin [Units/volume] in Serum or Plasma
3016-3 [3009201]
4.2e-01
—
—
—
—
7.9e-01
-2.3e-01
cases:14.29%
controls:9.90%
—
—
—
—
—
—
—
—
cases:10.94%
controls:5.26%
cases:15.25%
controls:18.49%
9
62
54
564
—
—
—
—
7
33
57
594
9
108
50
476
Guidance related to psychoactive substances / risk behaviour
SPAT1309 [2001700410]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.86%
—
—
—
—
—
—
0
5
59
579
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]
2.0e-01
8.3e-03
—
—
—
1.0e+00
-8.5e-02
cases:14.29%
controls:11.98%
cases:7.81%
controls:7.75%
—
—
—
—
—
—
cases:18.75%
controls:7.81%
cases:20.34%
controls:21.75%
9
75
54
551
5
49
59
583
—
—
—
12
49
52
578
12
127
47
457
Cells panel - Urine sediment
58434-2 [40761535]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.20%
—
—
—
—
—
—
0
7
59
577
diclofenac
D11AX18 [21602355]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.88%
—
—
—
—
—
—
0
11
59
573
Other gastroenteritis and colitis of infectious and unspecified origin
A09 [45605189]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.76%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
0
11
63
615
—
—
—
—
0
6
64
621
—
Neurology
13 [38004458]
1.2e+00
—
—
—
—
1.3e+00
-1.2e-01
cases:17.46%
controls:6.23%
—
—
—
—
—
—
—
—
cases:9.38%
controls:2.71%
cases:8.47%
controls:9.42%
11
39
52
587
—
—
—
—
6
17
58
610
5
55
54
529
desloratadine; oral
R06AX27 [21603526]
—
—
—
—
—
—
4.7e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.47%
controls:5.48%
—
—
—
—
—
—
5
32
54
552
Skin texture symptom/complaint
S21 [2002000986]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.37%
—
—
—
—
—
—
0
8
59
576
Administration of medicine
SPAT1254 [2001700355]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.03%
—
—
—
—
—
—
0
6
59
578
Complicated extraction of tooth
EBA05 [2001301924]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.60%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
63
616
—
—
—
—
—
—
Pain in throat
R07.0 [45592406]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.86%
—
—
—
—
—
—
0
5
59
579
temazepam; oral
N05CD07 [21604642]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:1.42%
—
—
—
—
—
—
cases:0.00%
controls:1.59%
—
—
—
0
9
64
623
—
—
—
0
10
64
617
—
Asthma
R96 [2002000961]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.86%
—
—
—
—
—
—
0
5
59
579
celecoxib
L01XX33 [21603805]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.60%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
63
616
—
—
—
—
—
—
rofecoxib; oral
M01AH02 [21603993]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.86%
—
—
—
—
—
—
0
5
59
579
Wrist X-ray examination
ND1AA [2001307576]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
63
621
—
—
—
—
—
—
Normoblasts [#/volume] in Blood
715-3 [3021589]
—
—
—
—
—
—
9.4e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:11.86%
controls:4.97%
—
—
—
—
—
—
7
29
52
555
Routine postpartum follow-up
Z39.2 [45547306]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.76%
cases:0.00%
controls:1.11%
—
—
—
—
—
—
—
—
—
—
0
11
63
615
0
7
64
625
—
—
—
—
—
Acute maxillary sinusitis
J01.0 [45601112]
—
—
—
—
—
—
7.4e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:10.17%
controls:5.14%
—
—
—
—
—
—
6
30
53
554
Need for immunization against other specified single viral diseases
Z25.8 [45547296]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
63
621
—
—
—
—
—
—
digoxin; oral, parenteral
C01AA05 [21600234]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
0
6
63
620
—
—
—
—
0
5
64
622
—
tramadol; oral, parenteral, rectal
N02AX02 [21604298]
—
1.7e+00
—
—
—
—
1.3e+00
—
—
cases:7.81%
controls:1.58%
—
—
—
—
—
—
—
—
cases:18.64%
controls:5.82%
—
5
10
59
622
—
—
—
—
11
34
48
550
Urinalysis macro (dipstick) panel - Urine
24357-6 [3037467]
2.4e-01
—
—
—
—
—
7.7e-01
cases:11.11%
controls:8.95%
—
—
—
—
—
—
—
—
—
—
cases:20.34%
controls:10.62%
7
56
56
570
—
—
—
—
—
12
62
47
522
Clinical & Laboratory Dermatological Immunology Physician
207NI0002X [38003841]
2.9e-01
—
—
—
—
—
4.9e-01
cases:7.94%
controls:6.07%
—
—
—
—
—
—
—
—
—
—
cases:10.17%
controls:6.51%
5
38
58
588
—
—
—
—
—
6
38
53
546
Comprehensive monitoring of chronic illness
SPAT1250 [2001700351]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.92%
—
—
—
—
—
—
—
—
—
—
—
—
0
12
63
614
—
—
—
—
—
—
Emergency Medicine
93 [38004510]
4.4e-01
—
—
—
—
9.4e-01
2.1e-02
cases:7.94%
controls:5.27%
—
—
—
—
—
—
—
—
cases:7.81%
controls:3.19%
cases:11.86%
controls:11.64%
5
33
58
593
—
—
—
—
5
20
59
607
7
68
52
516
Irradiated enamel
K03.80 [2000502698]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.86%
—
—
—
—
—
—
0
5
59
579
Audiology
64 [38004489]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
63
621
—
—
—
—
—
—
Anxiety disorder, unspecified
F41.9 [45542849]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
63
620
—
—
—
—
—
—
doxycycline; oral, parenteral
J01AA02 [21602800]
5.9e-02
—
—
—
-1.0e+50
—
6.4e-01
cases:14.29%
controls:13.58%
—
—
—
—
—
—
cases:0.00%
controls:0.79%
—
—
cases:28.81%
controls:17.64%
9
85
54
541
—
—
—
0
5
64
627
—
17
103
42
481
Migraine, unspecified
G43.9 [45595943]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.86%
—
—
—
—
—
—
0
5
59
579
Dental caries
K02 [45552906]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.03%
—
—
—
—
—
—
0
6
59
578
Glucose [Moles/volume] in Serum or Plasma
14749-6 [3013826]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:2.53%
—
—
—
—
—
—
—
—
—
—
—
0
16
64
616
—
—
—
—
—
Acute bronchitis, unspecified
J20.9 [45562445]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
63
620
—
—
—
—
—
—
insulin aspart; parenteral
A10AB05 [21600719]
—
-1.0e+50
-1.0e+50
—
-1.0e+50
—
—
—
—
cases:0.00%
controls:6.17%
cases:0.00%
controls:1.42%
—
—
cases:0.00%
controls:1.11%
—
—
—
—
—
0
39
64
593
0
9
64
623
—
0
7
64
625
—
—
Counselling related to known health issue
SPAT1310 [2001700411]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
—
—
—
—
—
0
5
64
627
—
—
—
—
—
Fetal Nuchal fold Thickness US
12146-7 [3005033]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
63
621
—
—
—
—
—
—
melatonin; oral
N05CH01 [21604659]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.28%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
63
618
—
—
—
—
—
—
Hysteroscopy
ULC02 [2001306644]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
63
621
—
—
—
—
—
—
Ferritin [Mass/volume] in Serum or Plasma
2276-4 [3001122]
—
—
—
—
—
1.6e+00
8.1e-01
—
—
—
—
—
—
—
—
—
—
cases:7.81%
controls:1.59%
cases:13.56%
controls:6.51%
—
—
—
—
—
5
10
59
617
8
38
51
546
Shortness of breath/dyspnoea
R02 [2002000883]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.20%
—
—
—
—
—
—
0
7
59
577
terbinafine; ointment
D01AE15 [21601954]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.03%
—
—
—
—
—
—
0
6
59
578
ethylmorphine; oral
R05DA01 [21603397]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
—
0
5
64
622
—
Pediatric Medicine
37 [38004477]
—
5.3e-01
—
—
—
7.5e-01
7.7e-01
—
—
cases:7.81%
controls:4.75%
—
—
—
—
—
—
cases:7.81%
controls:3.83%
cases:10.17%
controls:4.97%
—
5
30
59
602
—
—
—
5
24
59
603
6
29
53
555
atenolol; oral, parenteral
C07AB03 [21601685]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.96%
cases:0.00%
controls:1.11%
—
—
—
—
—
—
cases:0.00%
controls:0.96%
cases:0.00%
controls:0.86%
0
6
63
620
0
7
64
625
—
—
—
0
6
64
621
0
5
59
579
dapagliflozin; oral
A10BK01 [1123890]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
—
—
—
—
—
0
5
64
627
—
—
—
—
—
clindamycin; vaginal
G01AA10 [21602372]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
—
0
5
64
622
—
cefalexin; oral
J01DB01 [21602870]
3.1e-01
3.6e-01
—
—
-1.0e+50
8.5e-01
7.0e-01
cases:31.75%
controls:25.40%
cases:12.50%
controls:9.02%
—
—
—
—
cases:0.00%
controls:0.79%
cases:15.63%
controls:7.34%
cases:44.07%
controls:28.08%
20
159
43
467
8
57
56
575
—
—
0
5
64
627
10
46
54
581
26
164
33
420
dexamethasone; oral, parenteral
H02AB02 [21602730]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.03%
—
—
—
—
—
—
0
6
59
578
dexamethasone and antiinfectives
S02CA06 [21605178]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.86%
—
—
—
—
—
—
0
5
59
579
Skin symptom/complaint other
S29 [2002000993]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.60%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
63
616
—
—
—
—
—
—
etodolac; oral
M01AB08 [21603948]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
63
621
—
—
—
—
—
—
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
1.6e-01
-1.6e-01
—
—
1.8e+00
7.6e-01
2.1e-02
cases:12.70%
controls:11.02%
cases:7.81%
controls:9.02%
—
—
—
—
cases:7.81%
controls:1.42%
cases:15.63%
controls:7.97%
cases:18.64%
controls:18.32%
8
69
55
557
5
57
59
575
—
—
5
9
59
623
10
50
54
577
11
107
48
477
Functional dyspepsia
K30 [45591584]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.86%
—
—
—
—
—
—
0
5
59
579
COVID-19, virus not identified
U07.2 [45756094]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.44%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
63
617
—
—
—
—
—
—
Caries limited to enamel
K02.0 [45576967]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.60%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
63
616
—
—
—
—
—
—
levofloxacin
S01AE05 [43534860]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
63
621
—
—
—
—
—
—
naproxcinod
M01AE18 [40254094]
—
—
—
—
—
-1.0e+50
-3.2e-01
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:3.03%
cases:8.47%
controls:11.30%
—
—
—
—
—
0
19
64
608
5
66
54
518
Thorax X-ray examination
GD1AA [2001303617]
—
—
—
—
—
—
1.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:18.64%
controls:6.34%
—
—
—
—
—
—
11
37
48
547
Supervision of other normal pregnancy
Z34.8 [45537628]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.57%
—
—
—
—
—
—
0
15
59
569
hydrocortisone
S02BA01 [21605166]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.28%
—
—
—
—
—
—
—
0
8
64
619
—
esomeprazole; oral, parenteral
A02BC05 [21600100]
7.2e-01
1.4e+00
—
—
—
1.4e+00
1.1e+00
cases:11.11%
controls:5.75%
cases:9.38%
controls:2.37%
—
—
—
—
—
—
cases:9.38%
controls:2.39%
cases:18.64%
controls:7.19%
7
36
56
590
6
15
58
617
—
—
—
6
15
58
612
11
42
48
542
benzathine phenoxymethylpenicillin; oral
J01CE10 [21602850]
-2.3e-01
—
—
—
—
—
6.0e-01
cases:11.11%
controls:13.58%
—
—
—
—
—
—
—
—
—
—
cases:25.42%
controls:15.75%
7
85
56
541
—
—
—
—
—
15
92
44
492
Holo-transcobalamin II [Moles/volume] in Serum
72160-5 [43054903]
1.4e+00
—
—
—
—
-1.0e+50
—
cases:7.94%
controls:2.08%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.28%
—
—
5
13
58
613
—
—
—
—
0
8
64
619
—
Other spondylosis with radiculopathy
M47.2 [45591850]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.86%
—
—
—
—
—
—
0
5
59
579
Thyroperoxidase Ab [Units/volume] in Serum or Plasma
8099-4 [3027238]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.86%
—
—
—
—
—
—
0
5
59
579
Acute cystitis
N30.0 [45601724]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.37%
—
—
—
—
—
—
0
8
59
576
Vascular Surgery
77 [38004496]
—
—
—
—
—
—
1.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.47%
controls:1.88%
—
—
—
—
—
—
5
11
54
573
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
1.3e-01
—
—
—
—
2.2e-01
1.8e-01
cases:9.52%
controls:8.47%
—
—
—
—
—
—
—
—
cases:7.81%
controls:6.38%
cases:16.95%
controls:14.55%
6
53
57
573
—
—
—
—
5
40
59
587
10
85
49
499
Choriogonadotropin [Units/volume] in Serum or Plasma
19080-1 [3018171]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
63
621
—
—
—
—
—
—
Single live birth
Z37.0 [45571346]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.28%
cases:0.00%
controls:0.95%
—
—
—
—
—
—
—
—
—
—
0
8
63
618
0
6
64
626
—
—
—
—
—
Emergency procedure
ZXD00 [2001311385]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.12%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
63
619
—
—
—
—
—
—
Anogenital (venereal) warts
A63.0 [45585929]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.80%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.03%
0
5
63
621
—
—
—
—
—
0
6
59
578
Pharmacy visit
OMOP4822462 [581458]
3.3e-01
9.2e-01
6.2e-01
—
8.5e-01
5.2e-01
1.7e+00
cases:90.48%
controls:87.22%
cases:87.50%
controls:73.58%
cases:50.00%
controls:34.97%
—
—
cases:53.13%
controls:32.59%
cases:82.81%
controls:74.16%
cases:98.31%
controls:91.61%
57
546
6
80
56
465
8
167
32
221
32
411
—
34
206
30
426
53
465
11
162
58
535
1
49
Premature rupture of membranes, unspecified
O42.9 [45558306]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.03%
—
—
—
—
—
—
0
6
59
578
combinations of corticosteroids
D07AB30 [21602118]
4.6e-01
—
—
—
—
—
1.8e-01
cases:9.52%
controls:6.23%
—
—
—
—
—
—
—
—
—
—
cases:8.47%
controls:7.19%
6
39
57
587
—
—
—
—
—
5
42
54
542
Periodontal treatment, very brief
SDA01 [2001310326]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.56%
—
—
—
—
—
—
—
—
—
—
—
—
0
16
63
610
—
—
—
—
—
—
Opening and preparing the root canals
SGA02 [2001310380]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
63
621
—
—
—
—
—
—
estradiol; nasal, oral, parenteral, rectal, transdermal, vaginal
G03CA03 [21602517]
1.1e-01
—
—
—
-1.0e+50
2.7e-01
1.9e-01
cases:11.11%
controls:10.06%
—
—
—
—
—
—
cases:0.00%
controls:2.37%
cases:9.38%
controls:7.34%
cases:13.56%
controls:11.47%
7
63
56
563
—
—
—
0
15
64
617
6
46
58
581
8
67
51
517
amoxicillin; oral, parenteral
J01CA04 [21602823]
3.2e-01
2.5e-01
—
—
—
1.3e+00
8.5e-01
cases:25.40%
controls:19.81%
cases:7.81%
controls:6.17%
—
—
—
—
—
—
cases:17.19%
controls:5.42%
cases:40.68%
controls:22.60%
16
124
47
502
5
39
59
593
—
—
—
11
34
53
593
24
132
35
452
Acute sinusitis
J01 [45548098]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.03%
—
—
—
—
—
—
0
6
59
578
Bile acid [Moles/volume] in Serum --fasting
35562-8 [3034274]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
63
621
—
—
—
—
—
—
metoprolol; oral, parenteral
C07AB02 [21601684]
9.6e-01
—
—
—
—
—
6.1e-01
cases:7.94%
controls:3.19%
—
—
—
—
—
—
—
—
—
—
cases:8.47%
controls:4.79%
5
20
58
606
—
—
—
—
—
5
28
54
556
Other and unspecified skin changes
R23.8 [45573020]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.20%
—
—
—
—
—
—
0
7
59
577
Day surgery
ZXD20 [2001311388]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
63
620
—
—
—
—
—
—
naproxen and esomeprazole; oral
M01AE52 [40254096]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
63
620
—
—
—
—
—
—
frovatriptan; oral
N02CC07 [21604382]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.03%
—
—
—
—
—
—
0
6
59
578
fluticasone; nasal
R01AD08 [21605050]
—
—
—
—
—
—
6.0e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:16.95%
controls:10.10%
—
—
—
—
—
—
10
59
49
525
Postpartum check-up
SPAT1380 [2001700480]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.23%
—
0
5
64
627
—
—
—
—
0
13
59
571
Observation for suspected disease or condition, unspecified
Z03.9 [45552062]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
—
—
—
—
—
0
5
64
627
—
—
—
—
—
epinephrine
S01EA01 [21603673]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.95%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.37%
—
0
6
64
626
—
—
—
—
0
8
59
576
Choriogonadotropin.beta subunit free [Mass/volume] in Serum or Plasma
25373-2 [3019145]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
63
621
—
—
—
—
—
—
chloramphenicol
S01AA01 [21603554]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.44%
—
—
—
—
—
—
—
0
9
64
618
—
cefuroxime; oral, parenteral
J01DC02 [21602884]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.12%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
63
619
—
—
—
—
—
—
Bacteria identified in Blood by Culture
600-7 [3023368]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
—
0
5
64
622
—
Phakoemulsification with implantation of artificial lens in posterior chamber
CJE20 [2001301342]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.76%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
63
615
—
—
—
—
—
—
Abnormal findings on diagnostic imaging of lung
R91 [45548995]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.86%
0
6
63
620
—
—
—
—
—
0
5
59
579
Severe depressive episode without psychotic symptoms
F32.2 [45557202]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
63
620
—
—
—
—
—
—
Differential panel, method unspecified - Blood
69738-3 [42870588]
—
—
—
—
—
—
7.3e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.47%
controls:4.28%
—
—
—
—
—
—
5
25
54
559
Bicarbonate [Moles/volume] in Venous blood
14627-4 [3027273]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.86%
0
6
63
620
—
—
—
—
—
0
5
59
579
No disease
A97 [2002000230]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.44%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
63
617
—
—
—
—
—
—
Preventive oral health care, short
SCA01 [2001310302]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.44%
—
—
—
—
—
—
—
0
9
64
618
—
sumatriptan; nasal, oral, parenteral, rectal
N02CC01 [21604376]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.90%
—
—
—
—
—
—
—
—
—
—
—
0
12
64
620
—
—
—
—
—
lansoprazole; oral
A02BC03 [21600098]
9.1e-01
—
—
—
—
—
—
cases:7.94%
controls:3.35%
—
—
—
—
—
—
—
—
—
—
—
—
5
21
58
605
—
—
—
—
—
—
Hemoglobin [Mass/volume] in Venous blood
30350-3 [3004119]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.86%
0
6
63
620
—
—
—
—
—
0
5
59
579
azelastine; nasal
R01AC03 [21605035]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.12%
—
—
—
—
—
—
—
0
7
64
620
—
Short blood count panel - Blood
55429-5 [40758558]
—
—
—
—
—
—
1.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.47%
controls:2.91%
—
—
—
—
—
—
5
17
54
567
paroxetine; oral
N06AB05 [21604713]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.28%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
63
618
—
—
—
—
—
—
Dermatitis, unspecified
L30.9 [45572271]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.60%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
63
616
—
—
—
—
—
—
Psychiatry
26 [38004469]
6.9e-01
—
—
—
—
—
4.9e-01
cases:7.94%
controls:4.15%
—
—
—
—
—
—
—
—
—
—
cases:10.17%
controls:6.51%
5
26
58
600
—
—
—
—
—
6
38
53
546
formoterol and budesonide
R03AK07 [21603281]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.05%
—
—
—
—
—
—
0
12
59
572
bisoprolol; oral
C07AB07 [21601689]
—
—
—
—
—
-1.1e-01
3.6e-01
—
—
—
—
—
—
—
—
—
—
cases:7.81%
controls:8.61%
cases:15.25%
controls:11.13%
—
—
—
—
—
5
54
59
573
9
65
50
519
alendronic acid; oral
M05BA04 [21604152]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
63
621
—
—
—
—
—
—
Vaginal symptom/complaint other
X15 [2002001300]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
63
621
—
—
—
—
—
—
levothyroxine sodium; oral, parenteral
H03AA01 [21602754]
5.4e-01
—
-1.0e+50
—
-1.0e+50
6.3e-01
3.1e-01
cases:7.94%
controls:4.79%
—
—
cases:0.00%
controls:0.95%
—
—
cases:0.00%
controls:1.11%
cases:7.81%
controls:4.31%
cases:8.47%
controls:6.34%
5
30
58
596
—
0
6
64
626
—
0
7
64
625
5
27
59
600
5
37
54
547
Upper respiratory infection acute
R74 [2002000942]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.42%
—
—
—
—
—
—
—
—
—
—
—
0
9
64
623
—
—
—
—
—
Opening and preparing the root canals, complicated
SGA03 [2001310381]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.37%
—
—
—
—
—
—
0
8
59
576
amoxicillin and beta-lactamase inhibitor; oral, parenteral
J01CR02 [21602863]
—
—
—
—
—
—
1.7e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:10.17%
controls:8.73%
—
—
—
—
—
—
6
51
53
533
Cardiac arrhythmia, unspecified
I49.9 [45581778]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.86%
0
6
63
620
—
—
—
—
—
0
5
59
579
fluticasone; inhalant
R03BA05 [21603288]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.59%
—
—
—
—
—
—
—
0
10
64
617
—
SMOKING - SMOKE2: no - SMOKE3: former - SMOKE5: former
SMOKING-2-2-4 [2002330109]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.40%
—
—
—
—
—
—
—
—
—
—
—
—
0
15
63
611
—
—
—
—
—
—
Medical Oncology
90 [38004507]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.56%
—
—
—
—
—
—
—
—
—
—
—
—
0
16
63
610
—
—
—
—
—
—
Trisomy 18 risk [Likelihood] in Fetus
43994-3 [3047352]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
63
621
—
—
—
—
—
—
Thyroxine (T4) free [Moles/volume] in Serum or Plasma
14920-3 [3008486]
2.6e-01
—
—
—
—
8.3e-01
-2.5e-01
cases:11.11%
controls:8.79%
—
—
—
—
—
—
—
—
cases:9.38%
controls:4.31%
cases:11.86%
controls:14.73%
7
55
56
571
—
—
—
—
6
27
58
600
7
86
52
498
cromoglicic acid
S01GX01 [21605085]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.74%
—
—
—
—
—
—
0
16
59
568
Antenatal screening for fetal growth retardation
717801000 [36713463]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
63
620
—
—
—
—
—
—
insulin glargine; parenteral
A10AE04 [21600739]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.95%
—
—
—
—
—
—
—
—
0
6
64
626
—
—
Low back symptom/complaint
L03 [2002000628]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:3.94%
—
—
—
—
—
—
0
23
59
561
Headache
N01 [2002000720]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
0
6
64
621
—
Pneumonia, unspecified
J18.9 [45601123]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
63
621
—
—
—
—
—
—
Basophils [#/volume] in Blood
26444-0 [3006315]
7.0e-01
—
—
—
—
—
8.4e-01
cases:9.52%
controls:4.95%
—
—
—
—
—
—
—
—
—
—
cases:13.56%
controls:6.34%
6
31
57
595
—
—
—
—
—
8
37
51
547
epinephrine; parenteral
C01CA24 [21600303]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.95%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.37%
—
0
6
64
626
—
—
—
—
0
8
59
576
Nursing episode
950 [44777714]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.86%
—
—
—
—
—
—
0
5
59
579
Audiometric test
21727005 [4071702]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.86%
—
—
—
—
—
—
0
5
59
579
Neisseria gonorrhoeae DNA [Presence] in Specimen by NAA with probe detection
24111-7 [3011371]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.12%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
63
619
—
—
—
—
—
—
Choriogonadotropin [Units/volume] in Urine
25372-4 [3023511]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.20%
—
—
—
—
—
—
0
7
59
577
Vertigo/dizziness
N17 [2002000728]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.86%
—
—
—
—
—
—
0
5
59
579
Moderate depressive episode without somatic syndrome
F32.10 [2000501980]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.20%
—
—
—
—
—
—
0
7
59
577
naproxen; oral, rectal
M01AE02 [21603968]
—
—
—
—
—
-1.0e+50
-3.2e-01
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:3.03%
cases:8.47%
controls:11.30%
—
—
—
—
—
0
19
64
608
5
66
54
518
Biopsy of endometrium
LCA06 [2001306551]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.86%
—
—
—
—
—
—
0
5
59
579
Calculus of gallbladder with acute cholecystitis
K80.0 [45586735]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
63
621
—
—
—
—
—
—
Extensive health check-up on eighth grade
SPAT1386 [2001700486]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
—
—
—
—
—
0
5
64
627
—
—
—
—
—
General anaesthesia
WX402 [2001310806]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.28%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
63
618
—
—
—
—
—
—
Other primary coxarthrosis
M16.1 [45591741]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.86%
—
—
—
—
—
—
0
5
59
579
Blood group antibody screen [Presence] in Serum or Plasma
890-4 [3001079]
6.9e-01
—
—
—
—
—
8.1e-01
cases:7.94%
controls:4.15%
—
—
—
—
—
—
—
—
—
—
cases:11.86%
controls:5.65%
5
26
58
600
—
—
—
—
—
7
33
52
551
losartan; oral
C09CA01 [21601824]
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.37%
cases:0.00%
controls:0.79%
—
—
—
—
—
—
—
—
—
0
15
64
617
0
5
64
627
—
—
—
—
Carboxyhemoglobin/Hemoglobin.total in Venous blood
2032-1 [3010517]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.20%
—
—
—
—
—
—
0
7
59
577
Bacteria [#/volume] in Urine by Automated count
51480-2 [3031040]
6.0e-02
—
—
—
—
1.4e+00
5.5e-02
cases:7.94%
controls:7.51%
—
—
—
—
—
—
—
—
cases:10.94%
controls:3.03%
cases:11.86%
controls:11.30%
5
47
58
579
—
—
—
—
7
19
57
608
7
66
52
518
Dental calculus supragingival
K03.64 [2000502689]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:3.19%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.91%
—
—
0
20
63
606
—
—
—
—
0
12
64
615
—
Microorganisms panel - Urine sediment
58435-9 [40761536]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
63
621
—
—
—
—
—
—
Tissue transglutaminase IgG Ab [Units/volume] in Serum
32998-7 [3046870]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.03%
—
—
—
—
—
—
0
6
59
578
other preparations, combinations; ointment
C05AX03 [21601631]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
—
—
—
—
—
0
5
64
627
—
—
—
—
—
desogestrel
G03AC09 [21602505]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.96%
cases:0.00%
controls:0.95%
—
—
—
—
—
—
cases:0.00%
controls:0.96%
cases:0.00%
controls:2.91%
0
6
63
620
0
6
64
626
—
—
—
0
6
64
621
0
17
59
567
antibiotics in combination with corticosteroids
D01AA20 [21601918]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.20%
—
—
—
—
—
—
0
7
59
577
Type 1 diabetes mellitus, Without complications
E10.9 [45581351]
-1.0e+50
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:6.07%
—
—
—
—
—
—
cases:0.00%
controls:1.58%
—
—
—
—
0
38
63
588
—
—
—
0
10
64
622
—
—
Chronic coronary artery disease and dyslipidaemia associated with chronic coronary artery disease
206 [2001600204]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.28%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
63
618
—
—
—
—
—
—
Otitis externa, unspecified
H60.9 [45605727]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.86%
—
—
—
—
—
—
0
5
59
579
fluticasone, combinations
R01AD58 [43534837]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.12%
—
—
—
—
—
—
—
0
7
64
620
—
Child and Adolescent Psychiatry
OMOP4821986 [45756756]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
cases:0.00%
controls:0.80%
cases:0.00%
controls:1.54%
—
0
5
64
627
—
—
—
0
5
64
622
0
9
59
575
Observ/health educat/advice/diet
-45 [2002000116]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.86%
—
—
—
—
—
—
0
5
59
579
venlafaxine; oral
N06AX16 [21604745]
—
-1.0e+50
—
—
-1.0e+50
—
—
—
—
cases:0.00%
controls:1.27%
—
—
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
0
8
64
624
—
—
0
5
64
627
—
—
Feeling anxious/nervous/tense
P01 [2002000798]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.80%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.71%
0
5
63
621
—
—
—
—
—
0
10
59
574
Supplier / Service Provider
OMOP5117446 [33004]
-1.3e+00
—
—
—
—
—
—
cases:7.94%
controls:23.64%
—
—
—
—
—
—
—
—
—
—
—
—
5
148
58
478
—
—
—
—
—
—
Glucose tolerance 2 hours panel - Serum or Plasma
72171-2 [43054914]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
63
620
—
—
—
—
—
—
Albumin/Creatinine [Ratio] in Urine
32294-1 [3020682]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.90%
—
—
—
—
—
—
—
—
—
—
—
0
12
64
620
—
—
—
—
—
Base excess in Arterial blood by calculation
1925-7 [3003396]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.20%
—
—
—
—
—
—
0
7
59
577
diclofenac; oral, parenteral, rectal
M01AB05 [21603945]
-4.5e-01
—
—
—
—
—
-1.2e-02
cases:9.52%
controls:14.22%
—
—
—
—
—
—
—
—
—
—
cases:15.25%
controls:15.41%
6
89
57
537
—
—
—
—
—
9
90
50
494
Cholesterol [Moles/volume] in Serum or Plasma
14647-2 [3019900]
4.2e-02
—
—
—
—
—
-3.3e-01
cases:11.11%
controls:10.70%
—
—
—
—
—
—
—
—
—
—
cases:13.56%
controls:17.98%
7
67
56
559
—
—
—
—
—
8
105
51
479
General Surgery
2 [38004447]
6.1e-01
1.1e+00
—
—
—
1.2e+00
3.9e-01
cases:26.98%
controls:16.77%
cases:14.06%
controls:5.38%
—
—
—
—
—
—
cases:12.50%
controls:3.99%
cases:22.03%
controls:16.10%
17
105
46
521
9
34
55
598
—
—
—
8
25
56
602
13
94
46
490
ciprofloxacin; oral, parenteral
J01MA02 [21603009]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
0
6
64
621
—
Lumbar epidural anesthesia
WX306 [2001310796]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
63
621
—
—
—
—
—
—
estriol; oral, parenteral, vaginal
G03CA04 [21602518]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
63
621
—
—
—
—
—
—
Carcinoembryonic Ag [Mass/volume] in Serum or Plasma
2039-6 [3003785]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
63
621
—
—
—
—
—
—
valsartan and diuretics
C09DA03 [21601836]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.96%
cases:0.00%
controls:0.95%
—
—
—
—
—
—
cases:0.00%
controls:0.96%
cases:0.00%
controls:1.20%
0
6
63
620
0
6
64
626
—
—
—
0
6
64
621
0
7
59
577
Biopsy of vaginal cervix
LDA20 [2001306656]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
63
621
—
—
—
—
—
—
Benzodiazepines [Presence] in Urine
3390-2 [3000764]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.86%
—
—
—
—
—
—
0
5
59
579
ketoprofen; oral, parenteral, rectal
M01AE03 [21603969]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:1.90%
—
—
—
—
—
—
cases:0.00%
controls:1.75%
—
—
—
0
12
64
620
—
—
—
0
11
64
616
—
hydrocortisone
A07EA02 [21600654]
2.6e-01
—
—
—
—
—
—
cases:7.94%
controls:6.23%
—
—
—
—
—
—
—
—
—
—
—
—
5
39
58
587
—
—
—
—
—
—
One hour or less
ZXE00 [2001311394]
8.7e-01
—
—
—
—
—
—
cases:12.70%
controls:5.75%
—
—
—
—
—
—
—
—
—
—
—
—
8
36
55
590
—
—
—
—
—
—
olopatadine
R01AC08 [21605040]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.86%
—
—
—
—
—
—
0
5
59
579
SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection
94500-6 [706163]
—
—
—
—
—
—
3.7e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.47%
controls:5.99%
—
—
—
—
—
—
5
35
54
549
INR in Blood by Coagulation assay
34714-6 [3032080]
7.7e-01
—
—
—
—
2.2e+00
8.1e-01
cases:7.94%
controls:3.83%
—
—
—
—
—
—
—
—
cases:7.81%
controls:0.96%
cases:10.17%
controls:4.79%
5
24
58
602
—
—
—
—
5
6
59
621
6
28
53
556
apixaban; oral
B01AF02 [43534762]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.20%
—
—
—
—
—
—
0
7
59
577
Fracture of both the crown and the root
S02.54 [2000503621]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.86%
—
—
—
—
—
—
0
5
59
579
Tooth X-ray additional picture
EB1CA [2001301909]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.86%
—
—
—
—
—
—
0
5
59
579
Tissue transglutaminase IgA Ab [Units/volume] in Serum
31017-7 [3019050]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.44%
—
—
—
—
—
—
—
0
9
64
618
—
Albumin [Mass/volume] in Urine
1754-1 [3012516]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.58%
—
—
—
—
—
—
—
—
—
—
—
0
10
64
622
—
—
—
—
—
Cathetrisation of artery
TPH07 [2001309747]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.86%
—
—
—
—
—
—
0
5
59
579
orphenadrine (chloride); oral, parenteral
N04AB02 [21604458]
—
-1.0e+50
—
—
—
-1.0e+50
4.6e-01
—
—
cases:0.00%
controls:1.11%
—
—
—
—
—
—
cases:0.00%
controls:1.44%
cases:10.17%
controls:6.68%
—
0
7
64
625
—
—
—
0
9
64
618
6
39
53
545

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
51
168
5.11
14.99
9.1
2.5
0.76
0.79
mg/l
0.09
40
136
20
17
14.34
11.97
1.2
1.2
3.50
4.67
u/ml
—
12
9
18
12
17.93
11.84
2.5
1.9
—
—
—
0
0
15
12
14.43
9.21
1.2
1.1
—
—
—
0
0
57
270
3.55
9.06
7.6
2.9
2.38
2.36
mmol/l
0.87
52
242
65
336
3.62
8.96
10.5
5.2
38.13
36.73
g/l
1.34
59
326
72
440
3.22
6.76
8.5
8.3
0.04
0.04
e9/l
0.03
65
387
72
440
3.22
6.76
8.5
8.3
0.54
0.57
e9/l
0.79
65
387
53
276
2.94
6.62
8.5
8.0
—
—
—
0
0
72
448
3.11
6.39
8.5
8.4
1.87
1.89
e9/l
0.08
65
401
65
384
2.94
6.32
11.0
8.4
1.22
1.21
mmol/l
0.16
53
335
6
0
+∞
6.31
1.7
0.0
48.08
—
s
—
6
0
72
454
3.04
6.13
9.0
8.7
0.20
0.20
e9/l
0.04
65
405
64
382
2.84
5.99
11.5
12.1
0.00
0.00
e9/l
0.39
50
321
45
228
2.76
5.74
5.5
3.4
7.40
7.39
ph
0.08
38
162
19
58
3.80
5.64
4.3
3.6
72.13
62.20
e9/l
—
8
46
75
496
2.99
5.62
11.0
12.0
3.76
4.02
e9/l
0.69
66
435
11
16
7.57
5.11
2.5
3.4
6.50
5.14
index
—
6
7
64
416
2.47
4.54
10.4
7.2
10.75
11.29
umol/l
0.23
64
401
16
53
3.40
4.18
2.1
3.9
1.23
1.23
mmol/l
0.20
16
45
9
14
6.94
4.08
1.2
1.0
—
—
—
0
0
43
245
2.31
3.99
8.0
7.3
—
—
—
0
0
8
11
7.78
3.94
1.0
1.0
—
—
—
0
0
58
382
2.22
3.73
5.2
2.8
—
—
estimate
—
0
0
12
32
4.11
3.53
2.0
1.4
0.20
0.21
g/l
0.09
12
32
12
33
3.98
3.43
2.0
1.5
1.05
1.13
g/l
0.55
12
33
8
14
6.10
3.41
2.4
3.8
4.26
4.42
e9/l
—
8
14
37
214
2.15
3.19
4.4
6.8
—
—
—
0
0
50
331
2.01
2.96
18.7
9.3
1.24
1.20
inr
0.19
41
268
7
13
5.69
2.92
1.1
1.0
—
—
—
0
0
21
101
2.36
2.77
1.5
1.5
—
—
—
0
0
8
19
4.48
2.74
2.5
3.1
58.38
57.76
%
—
8
19
19
89
2.40
2.65
1.4
1.5
—
—
—
0
0
21
104
2.29
2.59
1.7
2.4
—
—
—
0
0
40
258
1.91
2.46
6.4
2.3
—
—
—
0
0
30
178
1.97
2.34
1.7
1.6
—
—
—
0
0
7
19
3.88
2.19
2.4
2.6
8.27
10.54
mg/l
—
7
19
95
853
2.91
2.13
22.0
13.5
19.37
22.31
mg/l
0.51
81
692
24
136
2.00
2.11
1.7
1.5
—
—
—
0
0
6
16
3.92
1.96
3.7
2.3
907.33
1580.50
e6/l
—
6
10
6
16
3.92
1.96
3.3
2.3
44.38
40.56
%
—
6
16
8
28
3.01
1.91
1.4
1.4
—
—
—
0
0
11
47
2.50
1.85
1.3
1.6
10.28
7.64
u/l
—
6
35
35
235
1.75
1.81
4.7
2.6
—
—
estimate
—
0
0
22
130
1.89
1.71
3.7
2.9
1.56
0.59
e6/l
0.49
16
63
5
14
3.70
1.63
1.0
1.0
1.36
1.29
g/l
—
5
14
94
858
2.38
1.60
25.5
15.3
139.96
139.78
mmol/l
0.44
94
845
94
859
2.36
1.60
25.8
15.4
3.96
3.97
mmol/l
0.26
94
844
35
244
1.66
1.55
4.7
2.8
0.14
0.24
e6/l
0.36
30
176
5
15
3.45
1.54
1.2
1.3
—
—
—
0
0
5
15
3.45
1.54
1.8
2.3
161.60
138.00
e6/l
—
5
10
18
103
1.91
1.53
11.9
8.2
105.56
103.70
mmol/l
1.26
18
103
29
196
1.67
1.44
4.8
4.2
—
—
—
0
0
12
61
2.10
1.39
2.8
1.9
1.02
1.17
g/l
0.31
12
56
5
17
3.04
1.37
1.4
1.4
29.36
19.18
ng/l
—
5
17
96
892
2.54
1.35
21.2
11.3
—
—
—
0
0
5
18
2.87
1.30
1.6
2.2
340.00
615.50
e6/l
—
5
10
41
309
1.55
1.29
2.2
2.0
100.50
93.82
pmol/l
0.44
24
154
5
19
2.71
1.23
4.0
2.2
—
—
—
0
0
16
95
1.81
1.22
1.8
1.5
—
—
—
0
0
8
38
2.20
1.21
18.0
17.6
95.34
93.91
%
—
8
38
12
66
1.93
1.14
5.7
3.0
—
—
—
0
0
34
255
1.50
1.07
2.6
3.0
50.82
73.29
u/l
0.69
34
243
6
28
2.21
0.93
1.0
2.1
68.33
229.80
ug/l
—
6
28
36
283
1.42
0.87
4.8
3.0
50.10
25.49
e6/l
0.44
31
216
60
516
1.40
0.87
6.0
4.3
—
37.67
—
0
12
20
144
1.48
0.75
1.4
1.3
37.86
2.52
u/ml
—
9
52
39
319
1.36
0.74
5.3
3.8
73.72
63.72
e6/l
0.06
31
227
14
95
1.55
0.68
3.8
2.1
325.86
367.18
nmol/l
0.37
14
88
10
62
1.68
0.68
1.9
1.5
—
—
—
0
0
32
258
1.35
0.65
1.8
1.4
—
—
—
0
0
26
205
1.36
0.61
2.0
1.6
1.61
2.15
g/l
1.60
19
132
28
225
1.34
0.58
1.9
2.1
—
—
—
0
0
12
82
1.53
0.57
16.6
12.2
—
—
—
0
0
95
913
1.68
0.55
28.8
16.3
74.58
76.85
umol/l
0.39
95
907
28
229
1.31
0.51
1.3
1.5
0.58
0.82
u/ml
—
9
74
7
46
1.56
0.49
1.1
1.2
—
—
—
0
0
7
47
1.53
0.49
2.6
1.7
—
—
—
0
0
21
166
1.33
0.48
1.3
1.2
20.82
21.60
iu/ml
—
6
44
20
248
0.76
0.46
2.8
3.2
—
—
—
0
0
5
32
1.59
0.43
2.4
1.3
—
—
—
0
0
5
33
1.54
0.42
23.0
15.2
1.22
1.33
mg/l
—
5
28
0
16
0.00
0.41
0.0
14.0
—
843.38
—
0
16
0
16
0.00
0.41
0.0
16.4
—
1453.81
—
0
16
6
45
1.35
0.34
1.0
1.1
—
—
—
0
0
7
56
1.27
0.30
24.1
11.0
23.39
24.98
mmol/l
—
7
56
12
94
1.31
0.29
1.3
1.3
—
—
—
0
0
28
247
1.18
0.26
3.6
3.6
0.00
0.01
estimate
0.49
17
90
49
453
1.16
0.26
3.2
3.4
0.00
0.00
estimate
-0.00
17
96
9
75
1.22
0.26
1.2
1.2
—
—
—
0
0
34
374
0.86
0.24
2.0
2.9
—
—
—
0
0
12
97
1.27
0.24
1.6
1.6
—
—
—
0
0
49
457
1.14
0.22
3.2
3.4
0.00
0.00
estimate
-0.00
16
90
0
11
0.00
0.21
0.0
4.0
—
80.82
—
0
11
0
10
0.00
0.21
0.0
1.6
—
—
—
0
0
0
10
0.00
0.21
0.0
8.3
—
6.76
—
0
10
0
12
0.00
0.21
0.0
7.0
—
11.52
—
0
12
48
449
1.13
0.20
3.2
3.3
0.00
0.00
estimate
-0.00
17
97
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
67
641
1.13
0.19
4.7
4.2
14.38
14.80
pmol/l
0.86
67
601
31
283
1.14
0.19
4.4
3.3
17.88
33.71
ng/l
0.72
20
179
10
82
1.24
0.18
2.1
1.5
—
—
—
0
0
12
102
1.20
0.16
1.2
1.1
—
—
—
0
0
39
365
1.11
0.15
2.5
3.0
6.30
6.12
ph
0.40
23
197
35
327
1.11
0.14
2.5
1.9
—
—
—
0
0
17
154
1.12
0.11
1.6
1.5
—
—
—
0
0
5
43
1.17
0.10
10.2
4.3
—
—
—
0
0
5
44
1.14
0.10
2.4
1.1
0.94
0.88
g/l
—
5
44
25
267
0.92
0.09
3.3
2.6
0.00
0.01
estimate
0.49
14
81
5
48
1.04
0.09
1.2
1.4
—
—
—
0
0
6
57
1.06
0.08
1.3
1.1
—
—
—
0
0
23
215
1.09
0.08
3.8
2.8
—
—
—
0
0
26
247
1.07
0.06
3.4
3.5
92.44
59.13
mg/l
0.26
18
159
36
347
1.06
0.06
2.9
3.1
0.00
0.01
estimate
0.49
14
86
17
167
1.02
0.00
2.9
2.8
0.58
0.70
ug/l
0.38
12
94
25
253
0.98
0.00
4.0
4.3
19.89
9.09
mg/mmol
0.43
18
162
12
125
0.95
0.00
1.5
2.1
—
—
—
0
0
0
8
0.00
0.00
0.0
2.9
—
107.13
—
0
8
0
8
0.00
0.00
0.0
2.9
—
1.20
—
0
8
0
8
0.00
0.00
0.0
2.9
—
4.09
—
0
8
0
7
0.00
-0.00
0.0
1.4
—
112.71
—
0
7
0
7
0.00
-0.00
0.0
3.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
4.8
—
11.77
—
0
6
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
4.9
—
58.07
—
0
7
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
0.02
—
0
5
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
7.34
—
0
5
0
7
0.00
-0.00
0.0
2.4
—
169.14
—
0
7
0
6
0.00
-0.00
0.0
1.0
—
29.46
—
0
6
0
6
0.00
-0.00
0.0
1.8
—
69.67
—
0
6
0
6
0.00
-0.00
0.0
1.0
—
160.60
—
0
6

Mortality – FinRegistry

↥

Association

Association between endpoint D3_HEREDFVIIIDEF and mortality.

Females

No data

Males

No data

Mortality risk

Mortality risk for people of age

years, who have D3_HEREDFVIIIDEF.

N-year risk Females Males
1 No data No data
5 No data No data
10 No data No data
15 No data No data
20 No data No data

Relationships between endpoints

↥

Index endpoint: D3_HEREDFVIIIDEF – Hereditary factor VIII deficiency

GWS hits: -

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data